Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SEGRO PLC. We currently have 3 research reports from 1 professional analysts.
|29Mar17 15:00||RNS||Total Voting Rights|
|28Mar17 15:00||RNS||Director/PDMR Shareholding|
|28Mar17 10:22||RNS||SUCCESSFUL PLACING OF RIGHTS ISSUE RUMP|
|28Mar17 07:00||RNS||RESULTS OF RIGHTS ISSUE|
|24Mar17 15:30||RNS||Director/PDMR Shareholding|
|23Mar17 15:30||RNS||Director/PDMR Shareholding|
|23Mar17 15:30||RNS||Trustee Market Purchase of Shares|
Frequency of research reports
Research reports on
H1 16: not bad at all
26 Jul 16
The group’s NRI stood at £120.9m, or up 4.1% lfl, with the UK outperforming once again the Continent, +6.2% lfl and +1% respectively, EPS was up 6.5% to 9.8p, and the interim dividend is increased by 4% yoy to 5.2p. The combined property portfolio at £5.9bn gained 1.5% (o/w 2.5% in Greater London, 1.2% in Southern Europe and 0.9% in CE). EPRA NAV gained 2.6% to 475p to now only 6% below our 18-months forward expectations. The financial position remains strong with net debt at £2.1bn including JVs and LTV down 36% (from 39% yoy). Overall, management maintains its confidence in its market despite the referendum, as long as occupational conditions remain strong. CFO Justin Read’s replacement will be Soumen Das (39), who will join company in January 2017.
Positive FY15 results, target raised to 484p from 473p
20 Feb 16
Segro published positive FY15 figures as expected: a rental lfl growth of 4.2% (o/w 5.2% from the UK and 1.2% from Continental Europe). PBT stood at £686.5m from £654.4m yoy, and EPS at 18.4p gained 7% yoy. The dividend stands at 15.6p (up 3.3% yoy) and the NAV gained 21% to reach 463p. Cost of debt stood at 3.7% from 4.4% yoy, net debt has increased to £1.8bn, however the LTV remained tamed at 38% from 40%. Management maintains its confidence in the positive momentum of its markets.
New target price of 495p following a solid H1
29 Jul 15
As anticipated, Segro published solid results in H1. The portfolio gained +5.8% on an lfl basis to £5.2bn and EPRA NAV now stands at 416p (up 8.3%). Adjusted PBT stands at £69.2m up 3.7% yoy, with EPS gaining 4.3% to 9.2p, better than we expected (our FY expectation was 17.7p). The interim dividend is increased to 5.0p form 4.9p yoy. The financial position remains strong with net debt at £1.8bn and an LTV down 1% to 39%.
28 Mar 17
ClearStar* (CLSU): Building a background for growth (CORP) | Sound Energy (SOU): TE-8 results (HOLD) | LiDCO* (LID): 2017 should be a transformative year (CORP) | Proteome Sciences* (PRM): FY 2016 in line. Moving towards breakeven (CORP) | Fulcrum (FCRM): Significant market potential, rising margins and a strong balance sheet (BUY) | Mortgage Advice Bureau (MAB1): Strong and growing intellectual property (BUY) | 7digital* (7DIG): Open offer result (CORP)
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
Small Cap Breakfast
28 Mar 17
Path Investments—Publication of prospectus from the Energy Investment Company. Raising £1.4m. Admission due on or around 30 March | Franchise Brands—Schedule 1 detailing £28m reverse takeover of Metro Rod. Admission expected 11 April | Alpha FX Group— Schedule 1 from the foreign exchange provider focused on managing exchange rate risk for UK corporates that trade internationally. Fundraise TBC. Admission expected 7 April. | K3 | Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. | Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Tufton | Oceanic Assets– Offer extended to 9 May to enable investors to complete further due diligence.
Small Cap Breakfast
23 Mar 17
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.